Replies to post #232992 on Biotech Values

[Fred Kadiddlehopper]

Thanks for posting that, Dew. EOM

[DewDiligence]

Re: RVNC / VTRS Botox biosimilar

During yesterday’s VTRS 3Q21 CC, COO Rajiv Malik said VTRS and RVNC met with the FDA in Sep 2021 and obtained the FDA’s buy-in on the clinical data and analytics needed for an eventual 351(k) submission, which VTRS expects to occur in 2024. Malik further said that RVNC’s Daxi CRL will not affect the timing of the Botox-biosimilar program.